
Pharma Wholesale and Distribution Market: World Outlook 2012-2022
NEW YORK, Aug. 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Pharma Wholesale and Distribution Market: World Outlook 2012-2022http://www.reportlinker.com/p0943306/Pharma-Wholesale-and-Distribution-Market-World-Outlook-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
Report Details Your guide to trends and revenue potential in pharma wholesaling and distributionWhere is the pharmaceutical wholesale and distribution (W&D) industry heading? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This new study investigates the W&D industry and its market environment. It lets you discover projected revenues at overall world market, main submarket, company and national level to 2022.
You see forecasts of world-level submarkets to 2022, finding potential revenue: • Original-branded drugs• Generic drugs.
How will 11 leading countries perform to 2022? You find W&D revenue forecasts, as well as discussions of what will drive and restrain those national markets:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• China
• Brazil
• Russia
• India.
You also find a revenue forecast to 2022 for the overall European W&D market.• Prospects for the pharma distribution chain from 2012 onwards
• Roles of pharmaceutical wholesalers
• Full-line wholesalers (FLWs)
• Short-line wholesalers (SLWs)
• Secondary wholesalers
• Direct-to-pharmacy distribution
• Pharmacy benefit managers
• Generating revenue and profit
• Emerging national markets
• Globalisation and increased demand for medicines.
The report also discusses these activities:• Forward buying• Fee-for-service activities• Serialisation for wholesalers• Specialty pharmaceuticals• Industry consolidation• Inventory management agreements and discounts• State-funded healthcare, reimbursements and clawbacks• Parallel trade and related issues• Impact of recent regulatory changes• Supermarket pharmacies, chain pharmacies and vertical integration• Pedigree legislation and using the supply chain to combat drug counterfeiting.
Market value for 2014 and prospects for the futureWhat does the future hold? The pharma industry and its supply chain partners will increase revenues from 2012 to 2022. Overall world revenue for wholesale and distribution activities will reach $747bn in 2014, the report forecasts.
What are companies doing? Our work profiles nine leading W&D organisations and investigates their revenue-generating prospects to 2022:
• McKesson
• Cardinal Health
• AmerisourceBergen
• The PHOENIX Group
• Alfresa Holdings
• Celesio
• Alliance Boots
• Suzuken
• Medipal.
The scope of the field widens, with organisations collaborating and expanding their businesses. Our investigation shows you commercial possibilities.
Increased unit sales of generic drugs will restrain revenue growth, as will direct-to-pharmacy distribution. Demand for specialty pharma products will augment sales, the study also finds.
There will be increasing dependence on emerging countries to 2022, with their fast-rising drug sales. Developed countries hold promise too.
New products - novel small molecules, generics and biologics - will stimulate the pharma sector. Many opportunities for rising drug sales exist, with high, growing W&D revenues possible from 2012 to 2022. Our report shows you and explains.
Forecasts, market shares, developmental trends, commercial news and discussionsIn visiongain's study you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and commercial developments. You receive 62 tables, 41 charts and two research interviews.
Eight ways Pharma Wholesale and Distribution Market: World Outlook 2012-2022 helps youIn particular, our report gives you the following knowledge on the topic:• Find potential revenues to 2022 for the overall world market and submarkets• Discover projected revenue trends to 2022 for nine leading companies• See market forecasting to 2022 for the US, Japan, EU5 countries, Brazil,Russia, China and India• Assess leading companies, and other players, discovering activities and outlooks• Review issues and events in the industry and market - emerging trends• Investigate competition and opportunities influencing unit sales and revenues• Find out what will stimulate and restrain the industry and market• View opinions from the industry, reading interviews from our survey.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use. Gain research and analysis now for the supply of medicinesOur study is for everybody needing industry and market analyses for the supply of pharmaceuticals. You find data, predictions and answers there. Please order that report now.
Table of Contents1.1 Overview of the Study
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. Introduction to the Market2.1 The Role of Pharmaceutical Wholesalers2.1.1 Full-Line Wholesalers (FLWs)2.1.2 Short-Line Wholesalers (SLWs)2.2 The Chain of Distribution2.2.1 Secondary Wholesalers2.2.2 Direct-to-Pharmacy2.2.3 Pharmacy Benefit Managers2.3 Generating Revenue and Profit2.3.1 Forward Buying2.3.2 Fee-for-Service2.3.2.1 Inventory Management Agreements2.3.3 Discounts 2.3.4 Reimbursement and Wholesalers2.3.5 Clawback2.3.6 Parallel Trade
3. The World Pharmaceutical Wholesale and Distribution Market, 2012-2022
3.1 The World Market in 2011
3.2 World Market Forecast, 2012-2022
3.3 Branded and Generic Drugs
3.3.1 Branded and Generic Drugs: Revenue Generation, 2011
3.3.2 Branded and Generic Drugs: Revenue Forecasts, 2012-2022
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2012-20224.1 The US4.1.1 An Increase in Fee-for-Service Activity4.1.2 US Market Forecast, 2012-20224.2 Europe4.2.1 Differences between the US and Europe4.2.1.1 State-Funded Healthcare and Reimbursement4.2.2 Europe and Leading EU Countries: Market Forecasts, 2012-2022 4.2.3 Germany4.2.3.1 Healthcare Reform4.2.3.2 Market Forecast, 2012-20224.2.4 France4.2.4.1 Market Forecast, 2012-20224.2.5 Spain4.2.5.1 Market Forecast, 2012-20224.2.6 The UK 4.2.6.1 Price Cuts4.2.6.2 Market Forecast, 2012-2022 4.2.7 Italy4.2.7.1 Market Forecast, 2012-2022 4.3 Japan4.3.1 Drug Pricing and Performance Fees4.3.2 Market Forecast, 2012-2022 4.4 China4.4.1 Leading Companies4.4.2 Recent Market Developments4.4.3 Market Forecast, 2012-2022 4.5 Brazil4.5.1 Leading Companies4.5.2 Market Forecast, 2012-20224.6 Russia4.6.1 Market Trends4.6.2 Market Forecast, 2012-2022 4.7 India4.7.1 Market Forecast, 2012-20224.8 Concluding Comments
5. Leading Pharma Wholesalers and Distributors in 2012
5.1 Revenue vs. Profit
5.1.1 Profit Margins
5.2 Leading Companies: Grouped Forecasts, 2012-2022
5.3 McKesson
5.3.1 Recent Performance
5.3.2 Future Strategies
5.3.3 Revenue Forecast, 2012-2022
5.4 Cardinal Health
5.4.1 Segment Reorganisation
5.4.2 Recent Performance
5.4.3 Future Strategies
5.4.4 Revenue Forecast, 2012-2022
5.5 AmerisourceBergen
5.5.1 Recent Performance
5.5.2 Future Strategies
5.5.3 Revenue Forecast, 2012-2022
5.6 The PHOENIX Group
5.6.1 Recent Performance
5.6.2 The Tamro Group 2011
5.6.3 Future Strategies
5.6.4 Revenue Forecast, 2012-2022
5.7 Alfresa Holdings
5.7.1 Recent Performance
5.7.2 Future Strategies
5.7.3 Revenue Forecast, 2012-2022
5.8 Celesio
5.8.1 Recent Performance
5.8.2 Future Strategies
5.8.3 Revenue Forecast, 2012-2022
5.9 Alliance Boots
5.9.1 Recent Performance
5.9.2 Future Strategies
5.9.3 Revenue Forecast, 2012-2022
5.10 Suzuken
5.10.1 Recent Performance
5.10.2 Future Strategies
5.10.3 Revenue Forecast, 2012-2022
5.11 Medipal
5.11.1 Recent Performance
5.11.2 Future Strategies
5.11.3 Revenue Forecast, 2012-2022
6. Qualitative Industry and Market Analyses, 2012-20226.1 Strengths6.1.1 Large Companies Dominate the Market6.1.2 Wholesalers Do More than Deliver Drugs6.1.2.1 Pre-Wholesaling6.2 Weaknesses6.2.1 Counterfeiting6.2.2 Low Margins6.3 Opportunities6.3.1 Increased Demand for Pharmaceuticals6.3.2 Generics6.3.3 Globalisation6.4 Threats6.4.1 Direct-to-Pharmacy (DTP)6.4.1.1 DTP in Europe6.4.1.2 The UK6.4.1.3 Poland6.4.1.4 DTP in Australia6.4.1.5 Further Expansion6.4.2 Healthcare Budget Cuts6.4.3 Diversion and Re-importation6.4.4 Supermarket Pharmacies6.4.4.1 Case Study: Walmart
7. Pharmaceutical Wholesale Industry Trends in 2012
7.1 Combating Counterfeit Medicines
7.1.1 The US and E-Pedigree
7.1.2 European Pedigree Legislation
7.1.3 Anti-Counterfeiting Strategies in Other Markets
7.1.4 Issues in Serialisation for Wholesalers
7.2 Growth in Specialty Pharmaceuticals
7.3 Industry Consolidation
7.4 Chain Pharmacies and Vertical Integration
7.5 Impact of Recent Regulatory Changes
8. Research Interviews8.1 Interview with Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)8.1.1 Key Unmet Needs8.1.2 Impact of Recent Regulatory Changes8.1.3 Value-Added Services8.1.4 Use of Novel Technologies8.2 Interview with Geoff Mellor and Martin Sawer, British Association of Pharmaceutical Wholesalers (BAPW)8.2.1 Recent Regulatory Changes8.2.2 Use of Technology8.2.3 Fast-Growing Sectors?
9. Conclusions from the Study
9.1 There Will Be Steady Growth in Developed National Markets
9.1.1 Generics Will Threaten Revenues
9.1.2 Manufacturers Will Deliver More Drugs Directly
9.1.3 There Will Be Greater Demand for Specialty Medicines
9.2 Growth Will Be Fastest in Emerging National Markets
9.2.1 Consolidation Will Drive Growth
9.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
9.4 Concluding Remarks
List of TablesTable 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 3.2 World Pharmaceutical W&D Market: Drivers and Restraints, 2012-2022
Table 3.3 Branded and Generic Drugs: Revenue Forecasts ($bn), 2011-2022
Table 3.4 Main Patent Expiries, 2011-2014
Table 3.5 Branded Drugs: Revenue Forecast ($bn), 2011-2022
Table 3.6 Generic Drugs; Revenue Forecast ($bn), 2011-2022
Table 3.7 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022
Table 4.1 Pharmaceutical Wholesale and Distribution Market: Sales ($bn) and Market Shares (%) by Country, 2011
Table 4.2 Pharmaceutical Wholesale and Distribution Market: Leading National Revenue Forecasts ($bn), 2011-2022
Table 4.3 US Market: Revenues ($bn) and Market Shares (%) by Company, 2011
Table 4.4 The US Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.5 US Market Drivers and Restraints, 2012-2022
Table 4.6 EU5 Pharmaceutical W&D Market by Country: Sales ($bn) and Market Shares (%), 2011
Table 4.7 Prominent Price Controls in Europe, 2012
Table 4.8 EU5 Pharmaceutical W&D Market: Forecasts ($bn), 2012-2022
Table 4.9 EU5 Market Drivers and Restraints, 2012-2022
Table 4.10 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.11 German Market Drivers and Restraints, 2012-2022
Table 4.12 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.13 French Market Drivers and Restraints, 2012-2022
Table 4.14 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022
Table 4.15 Spanish Market Drivers and Restraints, 2012-2022
Table 4.16 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022
Table 4.17 UK Market Drivers and Restraints, 2012-2022
Table 4.18 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.19 Italian Market Drivers and Restraints, 2012-2022
Table 4.20 Proportions (%) of Population Aged Over 65 Years by Region, 2025 and 2050
Table 4.21 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.22 Japanese Market Drivers and Restraints, 2012-2022
Table 4.23 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.24 Chinese Market Drivers and Restraints, 2012-2022
Table 4.25 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.26 Brazilian Market Drivers and Restraints, 2012-2022
Table 4.27 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.28 Russian Market Drivers and Restraints, 2012-2022
Table 4.29 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Table 4.30 Indian Market Drivers and Restraints, 2012-2022
Table 5.1 Leading W&D Companies: Revenues ($bn) and Market Shares (%), 2011
Table 5.2 Leading W&D Companies: Revenue Forecasts ($bn), 2011-2022
Table 5.3 W&D Market Leaders: Commercial Drivers and Restraints, 2012-2022
Table 5.4 McKesson Pharmaceutical Wholesale Revenue by Country ($bn), 2011
Table 5.5 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011
Table 5.6 McKesson Revenue Forecast ($bn), 2011-2022
Table 5.7 Cardinal Health Revenue Forecast ($bn), 2011-2022
Table 5.8 AmerisourceBergen Revenue Forecast ($bn), 2011-2022
Table 5.9 The PHOENIX Group: Wholesale Subsidiaries, 2010
Table 5.10 The Tamro Group, 2011
Table 5.11 The PHOENIX Group Revenue Forecast ($bn), 2011-2022
Table 5.12 Alfresa Wholesale Subsidiaries , 2011
Table 5.13 Alfresa Holdings Revenue Forecast ($bn), 2011-2022
Table 5.14 Celesio Wholesale Subsidiaries, 2010
Table 5.15 Celesio Wholesale Revenue ($bn) by Country, 2011
Table 5.16 Celesio Revenue Forecast ($bn), 2011-2022
Table 5.17 Alliance Boots Wholesale Revenue ($bn) by Country, 2011
Table 5.18 Alliance Boots Revenue Forecast ($bn), 2011-2022
Table 5.19 Suzuken Revenue Forecast ($bn), 2011-2022
Table 5.20 Medipal Revenue Forecast ($bn), 2011-2022
Table 6.1 SWOT Analysis of the World W&D Industry and Market, 2012-2022
Table 6.2 STEP Analysis of the World W&D Industry and Market, 2012-2022
Table 6.3 Strengths and Weaknesses of the DTP Model, 2012
Table 9.1 Overall Pharmaceutical Wholesale Revenue ($bn) and Market Shares (%) by Leading Country, 2011, 2015 & 2022
List of FiguresFigure 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 3.2 Branded Drugs: Revenue Forecast ($bn), 2011-2022
Figure 3.3 Generic Drugs: Revenue Forecast ($bn), 2011-2022
Figure 3.4 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022
Figure 4.1 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011
Figure 4.2 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2015
Figure 4.3 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2022
Figure 4.4 US Market Shares (%) by Leading Company, 2011
Figure 4.5 US Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.6 EU5 Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011
Figure 4.7 European W&D Market: Overall Revenue Forecast ($bn), 2011-2022
Figure 4.8 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.9 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.10 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022
Figure 4.11 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022
Figure 4.12 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.13 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
Figure 4.14 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.15 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.16 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.17 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 4.18 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
Figure 5.1 Leading W&D Companies: Market Shares (%), 2011
Figure 5.2 McKesson Pharmaceutical Wholesale Revenue (%) by Country, 2011
Figure 5.3 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011
Figure 5.4 McKesson Revenue Forecast ($bn), 2011-2022
Figure 5.5 Cardinal Health Revenue (%) by Company, 2011
Figure 5.6 Cardinal Health Revenue Forecast ($bn), 2011-2022
Figure 5.7 AmerisourceBergen Revenue Forecast ($bn), 2011-2022
Figure 5.8 The Tamro Group: Revenue Shares (%) by Country, 2011
Figure 5.9 The PHOENIX Group Revenue Forecast ($bn), 2011-2022
Figure 5.10 Alfresa Holdings Revenue Forecast ($bn), 2011-2022
Figure 5.11 Celesio Wholesale Revenue Shares (%) by Country, 2011
Figure 5.12 Celesio Revenue Forecast ($bn), 2011-2022
Figure 5.13 Alliance Boots Wholesale Revenues ($bn) by Country, 2011
Figure 5.14 Alliance Boots Revenue Forecast ($bn), 2011-2022
Figure 5.15 Suzuken Revenue Forecast ($bn), 2011-2022
Figure 5.16 Medipal Revenue Forecast ($bn), 2011-2022
Figure 6.1 Comparison of the Wholesaler and Direct-to-Pharmacy Routes, 2012
Figure 7.1 Anti-Counterfeiting Strategies in the US and Europe, 2012
Companies ListedAB Acquisitions Ltd
Acofarma (Asociación Cooperativas Farmacéuticas)
Admenta Italia
Alfresa Holdings Corp
Alfresa Medical Service Corp
Alfresa Nikken Sangyo
Alliance Boots
Alliance Healthcare
Alliance Santé
Alliance UniChem
Amedis-UE AG
AmerisourceBergen
Anderson Packaging
Ando Co.
Andreae-Noris Zahn (ANZAG)
Apokjeden
Australian Pharmaceutical Industries
Astellas Pharma
Astis Co
AstraZeneca
Athos Farma
Atol Co
Bayer
Bergen Brunswig
Brecon Pharmaceuticals
Bristol-Myers Squibb
British Association of Pharmaceutical Wholesalers (BAPW)
Brocacef Holding
Bundesverband des Pharmazeutischen Grosshandel
Cahill May Roberts
Cardinal Health
CareFusion
Celesio
Center for Medicine in the Public Interest
CERP network
Chambre Syndicale de la Répartition Pharmaceutique (CSRP)
China National Pharmaceutical Group (Sinopharm)
Chiyaku Co
Cipla
Cofares
Comifar Group
CS Yakuhin Co
CVS Caremark
Eli Lilly
European Association of Euro-Pharmaceutical Companies (EAEPC)
European Association of Pharmaceutical Full-line Wholesalers (GIRP)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Everlth Co.
Food and Drug Administration (US FDA)
Fukujin Co.
Galenica
GEHE Pharma Praha
GSK
Guangzhou Pharmaceuticals Corporation (GP Corp)
Healthcare Distribution Management Association (HDMA)
Hedef Alliance Holding
Hefame
Heisei Yakuhin Co.
Herba Chemosan
Hubei Kyoso Pharmaceutical
Humana
Huzhong Pharmaceutical Co.
HydraPharm
Inten
Izutsu Pharmaceutical Co.
Japanese Pharmaceutical Wholesalers Association
Jingu Yakuhin Co.
Jointown Pharmaceutical Group
Katren
Kemofarmacija
Kinray
Kobashou Co. (Kobayashi Group Company)
Kohlberg Kravis Roberts & Co.
Kowa Pharmaceuticals Co.
Kuraya Sanseido
Laboratoria Flandria
Libra
McKesson
Medco Health Solutions
Medicaid
MEDICEO CORPORATION
Medicine Shoppe International
MediPal
Meisho Co.
Merck & Co.
Mitsubishi
Miyagi Distribution Center
Nadro
Nakagawa Seikodo Co
Nakano Yakuhin Co
Napp Pharmaceutical
National Health Service (NHS UK)
Nomeco
Norsk Medisinaldepot
Novo Nordisk
OCP
Odashima
Oncology Therapeutics Network
Oncoprod
Panpharma
Parata Systems
Pfizer
Pharma Belgium
Pharmaceutical Security Institute (PSI)
PHOENIX Arzeiwarengro?handlung
PHOENIX Farmacija
PHOENIX Lékárensky
PHOENIX Medical Supplies
PHOENIX Pharma
PHOENIX Pharma Polska
PHOENIX Pharmahandel
PHOENIX Zdravotócke
Polska Grupa Farmaceutyczna
Profarma
Prosper
Protek
Ratiopharm
Rite Aid Pharmacy
Roche
Rosta
Ryuyaku Co
Sanacorp
Sanki Corporation
Sanofi
Seiwa Sangyo Co
Shanghai Pharmaceutical Co
Shikoku Alfresa Corp
Shoyaku Co
SIA International
Sigma Pharmaceuticals
Sincamesp
Sinopharm
State Food and Drug Administration (SFDA, China)
Suzuken
Suzuken Iwate Co
Suzuken Okinawa Yakuhin Co
Target
Teva
Institute for Pharmaeconomic Research (IPF)
The PHOENIX Group
The Tamro Group
Tjellesen Max Jenne
Toho Holdings
Torfarm
UniChem
US Oncology
Ushioda Sagokudo Yakuhin Co
Vitapharm
Walgreens Co.
Walmart
World Courier Group
Wyeth Pharmaceuticals (now part of Pfizer)
ZAO Rosta
Zuellig Pharma China (Yong Yu)
To order this report:Pharmaceutical Industry: Pharma Wholesale and Distribution Market: World Outlook 2012-2022Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article